Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totaling 23,029 shares, a drop of 37.5% from the May 31st total of 36,835 shares. Based on an average daily volume of 76,196 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $21.00.

Hedge Funds Weigh In On Neuphoria Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. AdvisorShares Investments LLC increased its stake in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after acquiring an additional 21,173 shares during the last quarter. Diadema Partners LP boosted its position in shares of Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock valued at $194,000 after acquiring an additional 28,548 shares during the last quarter. Ikarian Capital LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at $184,000. ADAR1 Capital Management LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at $116,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at $102,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Price Performance

NEUP opened at $3.38 on Friday. The firm has a 50-day simple moving average of $4.77 and a two-hundred day simple moving average of $4.42. Neuphoria Therapeutics has a 52 week low of $3.19 and a 52 week high of $21.40. The company has a market capitalization of $18.25 million, a PE ratio of -0.31 and a beta of 0.74.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. As a group, sell-side analysts expect that Neuphoria Therapeutics will post -4.07 earnings per share for the current year.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.